Healthcare - Biotechnology - NASDAQ - US
$ 7.74
-8.73 %
$ 475 M
Market Cap
-3.49
P/E
Price Target
Average
--100.00%
Revenue Forecast
Estimate
-0.00%
EBIT
Estimate
18.92%
Net Income
Estimate
26.33%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
Monte Rosa Therapeutics, Inc.
GLUE has no price targets from Wall Street.
REVENUE FORECAST
Revenue Forecast Chart GLUE
EBIT FORECAST
EBIT Forecast Chart GLUE
NET INCOME FORECAST
Net Income Chart GLUE